Valiant Organics Limited has released its Investor Presentation for Q2 FY2025-26 and H1 FY2025-26, highlighting a significant improvement in financial performance. * Consolidated Q2 FY26 Performance: * Operational Revenue was ₹1,573 million (₹157.3 crore). * Operating EBITDA stood at ₹212 million (₹21.2 crore), with a margin of 13.48%, a substantial increase from 1.50% in Q2 FY25. * Profit After Tax (PAT) was ₹57 million (₹5.7 crore), marking a strong recovery from a loss of ₹125 million (₹12.5 crore) in Q2 FY25. * Basic/Diluted EPS was ₹2.02 per share, compared to ₹(4.45) per share in Q2 FY25. * Consolidated H1 FY26 Performance: * Operational Revenue grew by 10.2% year-on-year to ₹3,617 million (₹361.7 crore). * Operating EBITDA was ₹459 million (₹45.9 crore), with a margin of 12.69%, up from 5.55% in H1 FY25. * PAT reached ₹139 million (₹13.9 crore), recovering from a loss of ₹131 million (₹13.1 crore) in H1 FY25. * Basic/Diluted EPS was ₹4.95 per share, compared to ₹(4.68) per share in H1 FY25. * Operational Highlights: * Revenue remained stable sequentially and showed healthy year-on-year growth, driven by better realizations and steady demand. * Gross Profit improved significantly to ₹718 million (₹71.8 crore), with gross margin expanding to 46% (from 39% in Q1 FY26 and 36% in Q2 FY25), due to better raw-material efficiency and an improved product mix. * Disciplined cost control, enhanced raw-material management, and reduced finance expenses contributed to healthy margin performance and a clear turnaround. * EBITDA saw substantial improvement, reflecting strong operating leverage. * Company Overview: Valiant Organics is a leading manufacturer of specialty chemicals for industries like agrochemicals, pharmaceuticals, dyes, pigments, and veterinary medications, with 6 manufacturing units and a total production capacity of 70,000 TPA.
